1. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets
- Author
-
Grégory Operto, Lorena Rami, Raffaele Cacciaglia, Alan Tucholka, Carles Falcon, José Luis Molinuevo, Gemma C. Monté-Rubio, and Juan Domingo Gispert
- Subjects
0301 basic medicine ,Oncology ,Male ,PLR, pairwise longitudinal registration ,ROI, region of interest ,Disease ,Neuropsychological Tests ,Preclinical Alzheimer's disease ,lcsh:RC346-429 ,preAD, preclinical Alzheimer's disease ,0302 clinical medicine ,Cerebrospinal fluid ,TIV, total intracranial volume ,Longitudinal Studies ,Cognitive decline ,10. No inequality ,ELISA, Enzyme-Linked ImmunoSorbent Assay ,t-tau, total tau ,Core (anatomy) ,Brain ,Regular Article ,Alzheimer's disease ,Middle Aged ,Magnetic Resonance Imaging ,CSF, Cerebro-Spinal Fluid ,DI, divergences of the longitudinal deformations ,Neurology ,Disease Progression ,lcsh:R858-859.7 ,Female ,AD, Alzheimer's disease ,FWE, Family Wise Error ,medicine.medical_specialty ,Cognitive Neuroscience ,p-tau, phosphorylated tau ,tau Proteins ,lcsh:Computer applications to medicine. Medical informatics ,03 medical and health sciences ,VBM, voxel-based morphometry ,Atrophy ,Alzheimer Disease ,Internal medicine ,Longitudinal VBM ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,WM, white matter ,CSF biomarkers ,lcsh:Neurology. Diseases of the nervous system ,Aged ,Amyloid beta-Peptides ,business.industry ,MMSE, Mini Mental State examination ,L, left ,R, right ,medicine.disease ,Ctrl, control ,Peptide Fragments ,030104 developmental biology ,ADNI, Alzheimer's Disease Neuroimaging Initiative ,Aβ42, amyloid beta ,Ageing ,CDR, Clinical Dementia Rating ,Csf biomarkers ,GM, gray matter ,Neurology (clinical) ,Preclinical stage ,business ,HCB, Hospital Clinic Barcelona ,030217 neurology & neurosurgery ,Biomarkers - Abstract
Alzheimer's disease (AD) is characterized by an accumulation of β-amyloid (Aβ42) accompanied by brain atrophy and cognitive decline. Several recent studies have shown that Aβ42 accumulation is associated with gray matter (GM) changes prior to the development of cognitive impairment, in the so-called preclinical stage of the AD (pre-AD). It also has been proved that the GM atrophy profile is not linear, both in normal ageing but, especially, on AD. However, several other factors may influence this association and may have an impact on the generalization of results from different samples. In this work, we estimate differences in rates of GM volume change in cognitively healthy elders in association with baseline core cerebrospinal fluid (CSF) AD biomarkers, and assess to what these differences are sample dependent. We report the dependence of atrophy rates, measured in a two-year interval, on Aβ42, computed both over continuous and categorical values of Aβ42, at voxel-level (p, Highlights • GM atrophy rates depends differently on values of CSF Aβ42 than on CSF p-tau in the preclinical stage of AD. • Discrepant results were obtained. Although nominally equivalent, samples might reflect different time-windows in the AD continuum. • It is necessary a further effort to standardize CSF-biomarkers measures and thresholds to make different samples to be directly comparable.
- Published
- 2018